Zacks Investment Research Lowers ProQR Therapeutics N.V. (PRQR) to Hold
Zacks Investment Research cut shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a buy rating to a hold rating in a research note issued to investors on Tuesday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
PRQR has been the topic of several other research reports. ValuEngine upgraded shares of ProQR Therapeutics N.V. from a strong sell rating to a sell rating in a research note on Friday, September 1st. HC Wainwright restated a buy rating and issued a $40.00 target price on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $14.30.
ProQR Therapeutics N.V. (PRQR) remained flat at $5.95 during trading on Tuesday. 37,913 shares of the stock were exchanged. The firm’s market capitalization is $143.42 million. ProQR Therapeutics N.V. has a 52 week low of $3.65 and a 52 week high of $8.70. The stock’s 50 day moving average is $5.08 and its 200 day moving average is $4.95.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Sphera Funds Management LTD. lifted its position in ProQR Therapeutics N.V. by 65.0% during the 1st quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after buying an additional 130,000 shares in the last quarter. Janus Henderson Group PLC acquired a new position in ProQR Therapeutics N.V. during the 2nd quarter worth about $2,028,000. Artal Group S.A. lifted its position in ProQR Therapeutics N.V. by 25.0% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 100,000 shares in the last quarter. Finally, Redmile Group LLC lifted its position in ProQR Therapeutics N.V. by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after buying an additional 43,050 shares in the last quarter. Institutional investors and hedge funds own 35.93% of the company’s stock.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.